Genentech, Inc.
NEWS
A U.S. FDA committee gave the nod to continue using Genentech’s checkpoint inhibitor Tecentriq in combination with chemotherapy to treat adults with mTNBC.
The U.S. Food and Drug Administration (FDA) approved a prefilled syringe for self-injection of an allergic diseases treatment developed by Novartis and Genentech, a Roche company.
There was a fair amount of clinical trial news last week. Here’s a look.
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 16, 2021.
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson’s disease, Alzheimer’s, HIV and more.
Genentech reported its rheumatoid arthritis drug Actemra failed to hit its primary endpoint in a COVID-19 trial, while Vir and GlaxoSmithKline’s antibody against COVID-19 demonstrated 85% efficacy.
The U.S. FDA approved Genentech’s Actemra (tocilizumab) for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 16, 2021.
JOBS
IN THE PRESS